RT Journal Article
SR Electronic
T1 Validation of an in vitro diagnostic test for endometriosis: impact of confounding medical conditions and lesion location
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.17.24305952
DO 10.1101/2024.04.17.24305952
A1 Daoud, Elza
A1 Archer, David F.
A1 Herranz-Blanco, Bárbara
YR 2024
UL http://medrxiv.org/content/early/2024/04/19/2024.04.17.24305952.abstract
AB With the aim to shorten the time for diagnosis and accelerate access to correct management, a non-invasive diagnostic test for endometriosis was developed and validated. The IVD test combines an ELISA test kit to quantify CA125 and BDNF concentrations in serum and a data treatment algorithm hosted in medical software processing results from the ELISA test and responses to six clinical variables. Serum samples and clinical variables extracted from psychometric questionnaires from 77 patients were collected from the Oxford Endometriosis CaRe Centre biobank (UK). Case/control classification was performed based on laparoscopy and histological verification of the excised lesions. Biomarkers serum concentrations and clinical variables were introduced to the software, which generates the qualitative diagnostic result (“positive” or “negative”). This test allowed the detection of 32% of cases with superficial endometriosis, which is an added value given the limited efficacy of existing imaging techniques. Even in the presence of various confounding medical conditions, the test maintained a specificity of 100%, supporting its suitability for use in patients with underlying medical conditions.Competing Interest StatementTwo authors (E.D. andB.H-B.) are employed by the company Exeltis (represented by Chemo Research S.L.).Funding StatementThis study was funded by Chemo Research S.L, Spain.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The experimental procedures received approval from the Ethics Committee of CEIm HM Hospitales (codes: 19.05.1411-GHM and 22.03.2001-GHM).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors